SCHEMBL734780

SCHEMBL734780

N#Cc1ccccc1OC(=O)c1ccccc1[C]=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ GAA P10253 3/20 0.41
▸ TSHR P16473 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ LPAR1 Q92633 1/20 0.40
▸ LPAR5 Q9H1C0 1/20 0.40
▸ MAPK14 Q16539 1/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ POLB P06746 2/20 0.39
▸ MAPT P10636 1/20 0.38
▸ TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755202 0.83 KMT2A (0.47) ALDH1A1HSD17B10KDM4EHPGDSMN1; SMN2
SCHEMBL11443998 0.81 SLC6A3 (0.60) ALDH1A1HSD17B10KDM4EHPGDSMN1; SMN2
SCHEMBL734781 0.80 PTGDR2 (0.42) ALDH1A1HSD17B10KDM4EHPGDSMN1; SMN2
SCHEMBL11431485 0.80 SCN1A (0.46) ALDH1A1HSD17B10KDM4EHPGDSMN1; SMN2
SCHEMBL3497886 0.79 HSD17B10 (0.63) ALDH1A1HSD17B10KDM4EHPGDSMN1; SMN2
SCHEMBL6567956 0.78 KMT2A (0.58) HSD17B10SMN1; SMN2GAATSHRLMNA
SCHEMBL124189 0.77 SMN1; SMN2 (0.49) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL733385 0.76 HSD17B10 (0.59) ALDH1A1HSD17B10KDM4EHPGDSMN1; SMN2
SCHEMBL11386163 0.76 TSHR (0.44) ALDH1A1KDM4EHPGDSMN1; SMN2GAA
SCHEMBL1697190 0.75 SMN1; SMN2 (0.47) ALDH1A1KDM4EHPGDSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138330-B2 Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite SIGMA-ALDRICH CO. LLC (US) 2012-03-20 — — US claimed
US-20080064867-A1 PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES SIGMA ALDRICH COMPANY (US) 2008-03-13 — — US claimed
US-8138330-B2 Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite SIGMA-ALDRICH CO. LLC (US) 2012-03-20 — — US disclosed
US-20080064867-A1 PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES SIGMA ALDRICH COMPANY (US) 2008-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064867-A1 PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES RNGTT, DUT, ADAR ALDH1A1 2127/4885HSD17B10 4283/4885KDM4E 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback